Brenus Pharma
Created in 2019
Up & running (A)
Existing signals show a regular activitySocial networks
26 4,241Activities
Technologies
Entity types
Location
Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 18
SIREN
802549030Engaged corporates
33
9 15Added in Motherbase
2 years, 1 month ago
biotech Value proposition
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide.
We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform.
Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide.
- Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies)
- We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply.
Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development.
We are currently envisaging clinical collaborations.
Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.
oncology, cancer, immune-therapy, innovation, cell therapy, healthtech, biotech, and cancervaccineOriginal language
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide.
We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform.
Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide.
- Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies)
- We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply.
Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development.
We are currently envisaging clinical collaborations.
Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.
Brenus Pharma
https://brenus-pharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 30 Nov 2024 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Other 8 Nov 2022 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 12 Feb 2024 | | |